NO20062358L - Combinations for the treatment of proliferative diseases - Google Patents

Combinations for the treatment of proliferative diseases

Info

Publication number
NO20062358L
NO20062358L NO20062358A NO20062358A NO20062358L NO 20062358 L NO20062358 L NO 20062358L NO 20062358 A NO20062358 A NO 20062358A NO 20062358 A NO20062358 A NO 20062358A NO 20062358 L NO20062358 L NO 20062358L
Authority
NO
Norway
Prior art keywords
treatment
proliferative diseases
combinations
cancer
drugs
Prior art date
Application number
NO20062358A
Other languages
Norwegian (no)
Inventor
Margaret S Lee
Curtis Keith
M James Nichols
Yanzhen Zhang
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/855,130 external-priority patent/US20050100508A1/en
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20062358L publication Critical patent/NO20062358L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Det beskrives kombinasjoner av medikamenter til behandlingen av proliferative sykdommer (f.eks. cancer). Det beskrives også fremgangsmåter for identifisering av nye kombinasjonsterapier til behandlingen av cancer og andre proliferative sykdommer.Combinations of drugs are described for the treatment of proliferative diseases (eg cancer). Methods are also described for identifying novel combination therapies for the treatment of cancer and other proliferative diseases.

NO20062358A 2003-11-12 2006-05-23 Combinations for the treatment of proliferative diseases NO20062358L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51955103P 2003-11-12 2003-11-12
US10/855,130 US20050100508A1 (en) 2003-11-12 2004-05-27 Methods for identifying drug combinations for the treatment of proliferative diseases
PCT/US2004/037527 WO2005046607A2 (en) 2003-11-12 2004-11-09 Combinations for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
NO20062358L true NO20062358L (en) 2006-07-12

Family

ID=34556562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062358A NO20062358L (en) 2003-11-12 2006-05-23 Combinations for the treatment of proliferative diseases

Country Status (13)

Country Link
EP (1) EP1689352A2 (en)
JP (1) JP2007524657A (en)
KR (1) KR20060118514A (en)
AR (1) AR046841A1 (en)
AU (1) AU2004289311A1 (en)
BR (1) BRPI0416390A (en)
CA (1) CA2545423A1 (en)
IL (1) IL175611A0 (en)
IS (1) IS8496A (en)
NO (1) NO20062358L (en)
RU (1) RU2006120491A (en)
TW (1) TW200526777A (en)
WO (1) WO2005046607A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663643B2 (en) * 2008-03-18 2014-03-04 Genentech, Inc. Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
WO2005046607A2 (en) 2005-05-26
JP2007524657A (en) 2007-08-30
TW200526777A (en) 2005-08-16
RU2006120491A (en) 2007-12-20
WO2005046607A3 (en) 2012-12-20
KR20060118514A (en) 2006-11-23
EP1689352A2 (en) 2006-08-16
IS8496A (en) 2006-06-02
CA2545423A1 (en) 2005-05-26
AR046841A1 (en) 2005-12-28
AU2004289311A1 (en) 2005-05-26
IL175611A0 (en) 2008-04-13
BRPI0416390A (en) 2007-02-21

Similar Documents

Publication Publication Date Title
EA202192738A1 (en) TRICYCLIC COMPOUNDS PROVIDING DESTRUCTION OF IKAROS PROTEIN AND AIOLOS PROTEIN
EA201792191A1 (en) FGFR / PD-1 COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMOR
DK1468014T3 (en) Compositions and Methods for WT1-Specific Immunotherapy
NO20062885L (en) Therapeutic anti-IGFR1 antibody combinations
NO2017019I1 (en) Diarylhydantoin compound, pharmaceutical composition and use thereof
NO20070782L (en) Tetrapeptidanaloger.
NO20055894L (en) Methods and compositions for the treatment of amyloid-related diseases
NO20072179L (en) Combination of an SRC kinase inhibitor and a. BCR-ABL inhibitor for the treatment of proliferative diseases
NO20073211L (en) Tibulin-binding anti-cancer drugs and their promedics
NO20093060L (en) Spirocyclic cyclohexane derivatives
NO20055832L (en) Preparation and use of arylalkyl acid derivatives for the treatment of obesity
EA200901313A1 (en) BLUTON TYROSINKINASE INHIBITORS
MY151032A (en) Treatment of tnf? related disorders
DE602005014127D1 (en) MEDICAL DEVICE AND MANUFACTURING METHOD THEREFOR
DE60319158D1 (en) PYRAZOLOISOQUINOLINE DERIVATIVES AS KINASE INHIBITORS
CY1109551T1 (en) PROTECTIVE SUSPENSIONS AND METHODS OF USING THESE
NO20055838L (en) Active variants of IL-18 binding protein and medical applications thereof
NO20092658L (en) New compounds
NO20060392L (en) Combination of SRC kinase inhibitors chemotherapeutic agents for the treatment of proliferative diseases
NO20071585L (en) New use of peptide compounds for the treatment of bone pain, chemotherapy and nucleoside induced pain
NO20055173L (en) Pharmaceutical combination combination comprising modafinil and another drug
DK1325011T3 (en) Methods and Compounds for the Treatment of Proliferative Diseases
NO20082425L (en) Formulations comprising jorumycin, reni-eramycin, safracin or saframycin-related compounds for the treatment of proliferative diseases
MX2021007235A (en) Tubulysins and protein-tubulysin conjugates.
NO20072285L (en) S-mirtazapine for the treatment of hot flashes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application